

### **REMARKS/ARGUMENTS**

By the present amendment, applicants have canceled Claims 4, 6, 10, 13, 16, 17, and 21. In addition, applicants have amended Claims 3, 5, 7-9, 11-12, 14-15, 19-20, 22-23, and 25 to correct either multiple dependencies or dependency. No new matter has been added. Therefore the claims remaining for consideration by the Examiner are Claims 1-3, 5, 7-9, 11-12, 14-15, 18-20, and 22-25.

Additionally, applicants have amended the specification to insert a claim of priority and place the Abstract on a separate sheet. Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7945

  
\_\_\_\_\_  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940

Date: January 7, 2005